MORE INFORMATION

▼
Tuesday, 19 August 2025

Blog postings will resume in September 2025

›
 Dear Grey Horizon readers,  Thank you for your continued support of this blog.  Postings will resume in September 2025.  

No survival benefit from adding adjuvant chemotherapy to endocrine therapy in older women with a genomic grade index high-risk ER-positive, HER2-negative breast cancer

›
Findings from ASTER 70s, a phase III randomized superiority study conducted on women 70 years or older "with a genomic grade index (GGI...
Thursday, 14 August 2025

ESMO joins the European Health Alliance on Alcohol (EHAA) to reduce preventable cancer cases linked to alcohol use

›
The European Society for Medical Oncology (ESMO) has joined the European Health Alliance on Alcohol (EHAA).  Classified as a group 1 carcino...
Thursday, 7 August 2025

Savolitinib plus osimertinib show a high response in EGFR-mutated NSCLC progressed on first-line osimertinib due to MET-driven resistance mechanisms

›
 Results of SAVANNAH, a phase II study comprised of "one of the largest datasets evaluating an oral MET tyrosine kinase inhibitor in EG...
Thursday, 31 July 2025

HER2 immunohistochemistry testing may not be needed in all solid tumours

›
 Results from a large-scale cohort study conducted on 65 000 patients with solid tumours undergoing pan-tumour HER2 immunohistochemistry (IH...
Wednesday, 23 July 2025

Breastfeeding patterns and relation to breast cancer outcomes after early, hormone receptor-positive breast cancer

›
 Findings from POSITIVE, the largest known study evaluating "breastfeeding frequency, patterns, and relation to breast cancer outcomes ...
Thursday, 17 July 2025

Adding retifanlimab to first-line chemotherapy for patients with advanced squamous cell anal cancer

›
An international, phase III study evaluating "efficacy and safety of retifanlimab in combination with standard carboplatin/paclitaxel i...
Wednesday, 9 July 2025

Measurable residual disease adapted consolidation strategy after quadruplet induction therapy for patients with newly diagnosed multiple myeloma

›
 Results of the phase III MIDAS study, conducted at the Universite de Toulouse in France, with findings reported at the American Society of ...
Wednesday, 2 July 2025

ESMO calls for oncology-specific safeguards in EU joint clinical assessments of medical and in vitro diagnostic devices in the new EU public consultation

›
The European Society for Medical Oncology (ESMO) has compiled a detailed response to the European Commission's public consultation draft...
Wednesday, 4 June 2025

Blog postings will resume in July 2025

›
  Dear Grey Horizon readers,  Thank you for your continued support of this blog.  Postings will resume in July 2025.  

Vepdegestrant results in longer PFS than fulvestrant in previously treated patients with ESR1-mutated, ER-positive, HER2-negative ABC

›
 Results from VERITAC-2, an open-label randomized phase III study conducted on "ER-positive HER2- negative advanced breast cancer patie...
Wednesday, 28 May 2025

Supplemental breast cancer imaging techniques could lead to earlier detection of cancer in women with dense breasts

›
 Results from the Breast Screening - Risk Adapted Imaging for Density (BRAID) study were recently published in The Lancet .  BRAID is "...
Wednesday, 21 May 2025

Patient and tumour characteristics may vary across treatment lines in a selected population of patients with mCRC included in randomised trials

›
 Findings from a large-scale study conducted via the Aide et Recherche en Cancerologie Digestive (ARCAD) database of patients with metastati...
Thursday, 15 May 2025

Sun safety declining in Canada amid rise in skin cancer cases

›
 A recently completed study from McGill University indicates a growing number of Canadians using less sun protection amidst increasing sun e...
Tuesday, 6 May 2025

InflaMix identifies CAR-T recipients with a preinfusion inflammatory profile indicative of high risk for CAR-T treatment failure

›
 Findings from the use of InflaMix, a predictive, point-of-care-clinical tool, designed "to identify patients at high risk of treatment...
Wednesday, 23 April 2025

Potential for larger gene panels to increase the number of molecularly matched therapies in patients with advanced solid tumours

›
 Results of ProfiLER-2, a multicentre, prospective study comparing a hospital homemade control gene panel (CTL) to "the commercially av...
Wednesday, 16 April 2025

Cancer mortality prediction for 2025 continues to show favourable trends in the European Union

›
 A recently completed study of cancer mortality rates across the European Union (EU) over the past 5 years (2020-2025) indicate a lower mort...
Thursday, 10 April 2025

Adding chemotherapy to radiotherapy not associated with improved OS for patients with intermediate-risk cervical cancer

›
 A population-based cohort study recently published in JAMA Oncology  found "no significant overall survival benefit from the addition ...
Wednesday, 2 April 2025

Suggesting a deadline in the invitation letter to FIT colorectal cancer screening results in more timely FIT return

›
 Results from the timeframe and planning tool (TEMPO) study, part of the Scottish Bowel Screening Program, has determined that "includi...
Wednesday, 19 March 2025

Real-world patients with cancer show lower survival times and treatment-associated survival benefits compared to those included in RCTs

›
 Findings from TrialTranslator, a machine-learning model involving randomized clinical trials (RCTs), indicates that "median overall su...
Wednesday, 12 March 2025

Distinct patient, tumour, treatment characteristics and a different pattern and risk of survival events over time between young BRCA1/2 carriers

›
 Findings from a large-scale 20-year multicentre hospital=based retrospective cohort study were recently published in Journal of Clinical On...
Thursday, 6 March 2025

Clinical benefit of pembrolizumab in patients with previously treated advanced clear cell gynaecological cancers

›
 Results from the United Kingdom-led PEACOCC phase II trial regarding the benefits of pembrolizumab on clear cell gynecological cancers was ...
Tuesday, 18 February 2025

Less frequent mammographic surveillance non-inferior compared with annual mammograms after diagnosis of breast cancer in women aged 50 years or older

›
 Results of Mammo-50, a randomized phase III trial conducted across the United Kingdom on women aged 50 or older was recently published in T...
Wednesday, 5 February 2025

Cancer prevention and screening account for most cancer deaths averted among different interventions across the cancer control continuum

›
 An extensive study of population-level mortality data, along with cancer prevention and screening interventions across common cancer in the...
Wednesday, 29 January 2025

Chemotherapy-free regimen of tucatinib and trastuzumab shows anti-tumour activity with durable responses in patients with HER2-mutated metastatic breast cancer

›
 Results of the open-label phase II trial, SGNTUC-019, "evaluating tucatinib in combination with trastuzumab" in patients with HER...
Wednesday, 22 January 2025

Active monitoring promising for women with low-risk ductal carcinoma in situ

›
Results of the intention-to-treat analysis from the COMET study, "a prospective randomized, pragmatic non-inferiority trial..." fo...
Monday, 16 December 2024

Blog postings will resume week of January 20, 2025

›
  Dear Grey Horizon readers,  Thank you for your support of the blog over the past year.  Postings will resume the week of January 20, 2025....

Lung adenocarcinoma with mucinous histology

›
 A recently completed study conducted amongst four academic institutions/cancer centres across the United States (Dana Farber/Brigham and Wo...
Tuesday, 10 December 2024

Prevention and screening have been major contributors to saving lives among five cancer types

›
 A recent study published in JAMA Oncology  focusing on mortality from breast, cervical, colorectal, lung, and prostate cancer indicates tha...
Wednesday, 4 December 2024

Adding pembrolizumab to preoperative radiotherapy and surgery improves disease-free survival for patients with stage III soft tissue sarcomas of the extremity

›
  Findings from the SU2C-SARC032 trial, conducted by the Sarcoma Alliance for Research through Collaboration (SARC) in 20 academic instituti...